Take our poll: How are you feeling as we near the New Year?
Tukysa + Standard Tx Improves Survival in Advanced HER2+
moderators
Posts: 8,741
Adding Tukysa to Standard of Care Continues To Improve Survival in Advanced-Stage HER2-Positive Breast Cancer
June 15, 2021
Adding Tukysa to the standard of care of Herceptin and Xeloda continued to improve both progression-free and overall survival in people diagnosed with either metastatic or unresectable locally advanced HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla. Read more...
0
Categories
Join Us on Zoom: Upcoming virtual meetups. Read more...
Give your account some personality! Add a profile photo.